Processa Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Processa Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 1 currently recruiting 5 completed early-phase tilt top decile by trial count

Processa Pharmaceuticals: 9 sponsored US clinical trials, 1 recruiting.

Processa Pharmaceuticals sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Tumor Gastric, with 1 trials.

Top-decile sponsor footprint

Processa Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 2

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

NCT06568692
COMPLETED Phase 2

Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis

NCT05270460
COMPLETED Phase 1

A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors

NCT04861987
TERMINATED Phase 2

A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

NCT04800562
COMPLETED Phase 2

A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica

NCT03698864
COMPLETED Phase 1

RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

NCT03189914
COMPLETED Phase 1

Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies

NCT02030067
TERMINATED Phase 2

Open Label Extension Study of HT-100 in Patients With DMD

NCT01978366
TERMINATED Phase 1

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy

NCT01847573

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 5

Therapeutic Areas

Tumor Gastric 1
Metastatic Bladder Cancer 1
TNBC - Triple-Negative Breast Cancer 1
HER2-Negative Breast Cancer 1
Advanced Cancer 1
Breast Cancer 1
Solid Tumor 1
Refractory Cancer 1

What is open in the Processa Pharmaceuticals pipeline

1 recruiting of 9 indexed (11% open); 5 completed (56%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Tumor Gastric (1 trial), 7 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Processa Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Processa Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40%50% Total trials Recruiting share Processa Pharmaceuticals4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyADC Therapeutics S.A.Adrian VellaAIDS Malignancy ConsortiumAmylyx Pharmaceuticals
Processa Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Processa Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Processa Pharmaceuticals page

9 registered trials is a research-attention snapshot, not an endorsement of Processa Pharmaceuticals or any single study.

  • 1 of Processa Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Tumor Gastric is the condition Processa Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Tumor Gastric trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Processa Pharmaceuticals pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.